Records containing: Non Small Cell Lung Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-11-17A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2025-11-17A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-11-05A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2025-11-04A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M17D1 in Subjects With HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-29Biology of Young Lung Cancer Study: The YOUNG LUNG Study
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-10-28SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
-
CLINICAL_TRIALS study record update · 2025-10-24Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
-
CLINICAL_TRIALS study record update · 2025-10-16A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
-
CLINICAL_TRIALS study record update · 2025-10-09RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3
-
CLINICAL_TRIALS study record update · 2025-10-08Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening
-
CLINICAL_TRIALS study record update · 2025-10-07Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
-
CLINICAL_TRIALS study record update · 2025-10-06Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-03Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-10-02A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
-
CLINICAL_TRIALS study record update · 2025-10-02A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations
-
CLINICAL_TRIALS study record update · 2025-10-02Circulating DNA to Improve Outcome of Oncology PatiEnt: A Randomized Study - COPE Study
-
CLINICAL_TRIALS study record update · 2025-09-30A Multi-center Retrospective Study of the Mechanism of Acquired Resistance in First Line Treatment of ROS1fusion Positive NSCLC With Entrectinib
-
CLINICAL_TRIALS study record update · 2025-09-29A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
-
CLINICAL_TRIALS study record update · 2025-09-26A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Chemotherapy in the Treatment of EGFR WT and ALK WT Recurrent and Metastatic Non-small Cell Lung Cancer
-
CLINICAL_TRIALS study record update · 2025-09-26A Prospective, Single-Arm Phase II Clinical Trial of Standard Systemic Therapy Combined With Spatial Fractionated Radiotherapy (SFRT) for Oligoprogressive Non-small Cell Lung Cancer (NSCLC)
-
CLINICAL_TRIALS study record update · 2025-09-25Improvement of the Value of Orally Administered Cancer Drugs: Arm 1: Osimertinib for Advanced EGFR-positive NSCLC Patients: A Phase II Study
-
CLINICAL_TRIALS study record update · 2025-09-24A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation
-
CLINICAL_TRIALS study record update · 2025-09-24A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
-
CLINICAL_TRIALS study record update · 2025-09-19A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of JYP0322 Versus Platinum-Based Chemotherapy in ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Previously Treated With ROS1-TKI Therapy.
-
CLINICAL_TRIALS study record update · 2025-09-19Benefits Study of a Respiratory Gating Protocol for Positron Emission Tomography: Application on the Lungs